Endothelin-A Receptor Antagonism Modifies Cardiovascular Risk Factors in CKD

Neeraj Dhaun, Vanessa Melville, Scott Blackwell, Dinesh K Talwar, Neil R Johnston, Jane Goddard, David J Webb

Research output: Contribution to journalArticlepeer-review


Arterial stiffness and impaired nitric oxide (NO) bioavailability contribute to the high risk for cardiovascular disease in CKD. Both asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO production, and endothelin-1 (ET-1) oppose the actions of NO, suggesting that ET-1 receptor antagonists may have a role in cardiovascular protection in CKD. We conducted a randomized, double-blind, three-way crossover study in 27 patients with proteinuric CKD to compare the effects of the ET(A) receptor antagonist sitaxentan, nifedipine, and placebo on proteinuria, BP, arterial stiffness, and various cardiovascular biomarkers. After 6 weeks of treatment, placebo and nifedipine did not affect plasma urate, ADMA, or urine ET-1/creatinine, which reflects renal ET-1 production; in contrast, sitaxentan led to statistically significant reductions in all three of these biomarkers. No treatment affected plasma ET-1. Reductions in proteinuria and BP after sitaxentan treatment was associated with increases in urine ET-1/creatinine, whereas reduction in pulse-wave velocity, a measure of arterial stiffness, was associated with a decrease in ADMA. Taken together, these data suggest that ET(A) receptor antagonism may modify risk factors for cardiovascular disease in CKD.
Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalJournal of the American Society of Nephrology
Issue number1
Publication statusPublished - 28 Dec 2012


Dive into the research topics of 'Endothelin-A Receptor Antagonism Modifies Cardiovascular Risk Factors in CKD'. Together they form a unique fingerprint.

Cite this